The mixed results are a blow for bepranemab and for related antibodies that target a mid-region epitope on tau. But exploratory analyses of the results hint at a path forward for these candidates.

The company aims to supercharge antibody treatments using specially designed protein “cages” that multiply their effects, opening up new opportunities in drug development. The company was spun ...

Ueda is holding an expandable toy that he uses to demonstrate how the company’s computationally designed Antibody Cages work. (GeekWire Photo / Alan Boyle) Three weeks after University of ...

Therapeutic antibodies are an important alternative option, but resistance has developed owing to the emergence of viral variants. A new paper in Cell reports the development of an antibody with ...

Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi 465-8603, Japan Exploratory Research Center on Life and Living Systems (ExCELLS), National Institutes of Natural ...